Related Experiment Videos
[Intracoronary thrombolysis in myocardial infarction]
Insights
Intracoronary thrombolysis effectively dissolves coronary artery thrombi, improving left ventricular function when administered within 4 hours. Early intervention and collateral circulation enhance outcomes, though recurrence and risks necessitate further research into long-term benefits and comparisons with intravenous methods.
Area of Science:
- Cardiology
- Interventional Cardiology
- Thrombosis Research
Context:
- Myocardial infarction is frequently caused by coronary artery thrombi.
- Intracoronary fibrinolytic therapy offers a treatment option for acute thrombus dissolution.
- Timeliness of intervention is critical for optimal left ventricular functional recovery.
Purpose:
- To evaluate the efficacy and safety of intracoronary thrombolysis for myocardial infarction.
- To identify factors influencing treatment success, such as timing and collateral circulation.
- To compare intracoronary thrombolysis with conventional treatments and explore strategies to prevent recurrence.
Summary:
- Intracoronary thrombolysis dissolves coronary thrombi in over 70% of myocardial infarction cases.
- Optimal left ventricular function improvement requires administration within 4 hours; later treatment yields inconsistent results.
- While risks like hemorrhage exist, mortality is lower than conventional therapy. Early intervention and collateral circulation correlate with better ejection fraction improvement.
- Recurrence rates of 15-20% can be managed with early aorto-coronary bypass or transluminal angioplasty.
- Further multicenter trials are needed to confirm long-term survival benefits and compare efficacy against intravenous thrombolysis.
Impact:
- Intracoronary thrombolysis demonstrates potential for improved outcomes in acute myocardial infarction compared to conventional treatments.
- Identifying optimal treatment windows and patient selection criteria can maximize therapeutic benefits.
- Preventive strategies against thrombosis recurrence are crucial for sustained cardiac health.
- The findings underscore the need for comparative effectiveness research to establish the definitive role of intracoronary thrombolysis in clinical practice.
Abstract:
In more than 70% of the cases thrombi in the coronary arteries responsible for myocardial infarction can be dissolved by intracoronary injection of a fibrinolytic agent. For the left ventricular function to improve thrombolysis must be performed within 4 hours of thrombus formation; when performed later, results are inconstant. The risks of arteriography and thrombolysis (mostly dysrhythmias and haemorrhage) are real but acceptable. The mortality rate is lower than with conventional treatment. Improvement in left ventricular global ejection fraction is more pronounced in cases with collateral circulation and when thrombolysis is performed at an early stage. Thrombosis recurs within a few days in 15-20% of the cases. This can be prevented by aorto-coronary bypass or transluminal dilation of the stenotic vessel with a balloon catheter, either of these being carried out very early in cases with tight stenosis or delayed when the stenosis is significant but not life-threatening. A multicentre trial should be set up to find out whether intracoronary thrombolysis improves long-term survival and prevents late complications. But even if this were true, it should still be demonstrated that the method is as effective and safe as intravenous thrombolysis.